Insulatard Innolet

Insulin human, the active ingredient in Insulatard Innolet, is an insulin presented as a 100 IU/mL solution for injection for subcutaneous use. It treats diabetes mellitus in both type 1 and type 2 patients.

GNH USA supplies Insulatard Innolet as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Insulatard Innolet, a long‑acting insulin, is used to manage blood glucose in diabetes mellitus.

- Type 1 diabetes mellitus: provides basal insulin coverage to maintain fasting glucose levels. - Type 2 diabetes mellitus: complements oral agents or rapid‑acting insulin to achieve overall glycaemic control. - Hospitalised hyperglycaemia: supplies basal insulin for patients requiring stable glucose management during inpatient care.

Common Side Effects: - Hypoglycaemia: low blood glucose episodes, especially if meals are missed or dosing is excessive. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: modest increase due to improved glucose utilisation. - Lipodystrophy: localized changes in subcutaneous fat with repeated injections.

Serious or Rare Side Effects: - Severe hypoglycaemia with seizures or loss of consciousness. - Anaphylactic reaction: systemic allergic response requiring immediate medical attention. - Insulin antibodies: may alter insulin efficacy or cause hypersensitivity. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: rare severe skin reactions. - Acute metabolic acidosis: very rare but potentially life‑threatening.

Before using Insulatard Innolet, consider the following precautions: - Dose adjustment: modify the dose in renal or hepatic impairment to avoid hypoglycaemia. - Blood‑glucose monitoring: check glucose levels frequently, especially when initiating therapy. - Hypoglycaemia unawareness: use caution in patients who cannot recognise low‑glucose symptoms. - Pregnancy and lactation: safety category is unknown; weigh benefits against potential risks. - Concomitant medications: review drugs that may potentiate or mask hypoglycaemia. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Insulatard Innolet may interact with other medicines as follows:

Major Interactions (Avoid): - Sulfonylureas or meglitinides: combined use can cause severe hypoglycaemia. - Alcohol: may potentiate insulin’s glucose‑lowering effect and increase hypoglycaemia risk. - Beta‑blockers: can mask typical hypoglycaemia symptoms such as tachycardia.

Moderate Interactions (Monitor Closely): - Corticosteroids: may raise blood glucose, requiring insulin dose adjustments. - Thyroid hormones: can alter insulin requirements, necessitating close monitoring. - Diuretics (especially thiazides): may affect potassium levels and insulin sensitivity. - ACE inhibitors or ARBs: may influence potassium balance and require periodic checks.